FDA Ad and Promo Enforcement Targets Presentation of Risk Info, Pre-Approval Promotions

Drug Industry Daily
Recent FDA warnings and untitled letters show the agency’s enforcement efforts for advertising and promotion are focused on product risk information and pre-approval promotions for investigational drug products, according to two Ropes and Gray attorneys.

To View This Article:


Subscribe To Drug Industry Daily